admin – Page 4286 – Get News Story

Sweet C Talks About Her New Single Left Hand Of The Devil

Over the years I have interviewed lots of artists and bands, and been to many concerts, but one artist that you may never have heard of has took me back to what real music is all about. Forget the gimmick, forget the technical equipment to improve voices, this artist has a voice that doesn’t need any special effects.

She has been described as one of the most exciting unsigned artists on the planet, and her new song Left Hand Of The Devil, is the best new single I have listened to in the past 12 months, and trust me, I have to listen to a lot of music.

But who is this artist I am talking about. Her name is Sweet C. I was lucky enough to sit down with Sweet C and talk about her new song Left Hand Of The Devil, and this is what she had to say.

What was the first single or album you bought?

I honestly don’t remember, I’m 52 years old and grew up too poor to buy music. I listened to mix tapes we recorded from the radio.

What was the first concert you went to and how old were you and did it have an impact on you wanting to have a career in music?

I believe it was Jaci Velasquez. Sometime in my teenage years. Yes, I wanted to become a singer back then as well.

What age were you when you decided to make music your career?

I always loved to sing and wrote my first song in 1990. Life was a struggle for me though, so I waited until I retired from the USAF at the age of 47 to pursue this dream.

How would you describe your style of music?

Very unique and multi genre.

When I listened to your new track Left Hand Of The Devil, it reminded me of so many great artists and bands rolled into one, which includes Fleetword Mac, and KT Tunstall, who would you say are your influences in music and have any of them influenced your sound?

I hear that a lot about Fleetwood Mac. Several people have told me my voice reminds them of Stevie Nicks. I just recently started listening to her though so I wouldn’t say she has influenced me but I do love her music now. I listen more to Christian artists like Lauren Daigle and Katy Nichole. I also love to sing Whitney Houston and Shania Twain for Karaoke.

Talking of your new track Left Hand Of The Devil, which I have to say I love, how did you come up with the song and can you explain the meaning behind the song?

The words hit me like a wave last year when I had growing concerns about our political choices running for President. I’m a Christian and have seen how the Jezebel Spirit has infiltrated politics causing many people to make bad policies that are clearly evil and will lead us to the One World Order. I wanted to create a song to wake up the sleepy Christians who are blinded to see evil for evil and good for good.

I love it that you are not only a talented songwriter, but you are also a poet, has poetry helped you in your craft of writing music?

Yes, every song has started out as a poem. The hard part for me is creating the melody which is more of a challenge for me.

What is one thing about your life your fans don’t know about and what may surprise them?

I’m pretty transparent and reveal a lot of personal testimonies on my YouTube channel. I suppose one thing about me my fans do not know yet is that I’m a black belt in karate. I stopped training many years ago but I could still hold my own if I had to.

Yes, two of my songs were written while I was deployed on two separate deployments. That was my therapy which helped me get through it.

What would you say has been the highlight of your musical career to date?

The highlight of my music career so far has been getting told by a fan that my song “Let Him Live” touched her while she was going through a similar situation with her pregnancy.

When you write your songs, what comes first, the music or the lyrics?

The lyrics have always come first for me. That is the most natural process for me.

If you could get on stage with any singer in the world, who would it be and why?

I would love to share a stage with Scotty Hasting. He is a new and awesome country singer as well as a fellow military veteran.

Are there any plans to release an album and if so, what can we expect?

Yes, I plan to release an album sometime this year. It will be a collection of most of my current songs along with at few new ones. I will sell that in vinyl and CD formats on my website at www.sweetcmusic.com

Check out The Left Hand Of The Devil here https://youtu.be/NPMxVdPwXNo?si=YDOKp0IVCmVgQggx

Media Contact
Company Name: Sweet C
Contact Person: Media Manager
Email: Send Email
Country: United States
Website: www.sweetcmusic.com

AEGIS Cybersecurity Systems Inc. Announces $10 Million Investment

McLean, Virginia – AEGIS Cybersecurity Systems Inc., a leader in technology innovation, announces the successful completion of its target $10 million investment fundraising initiative to support accelerating commercial roll-out, including marketing and sales and key recruiting initiatives. This milestone marks a significant step forward in the company’s mission: “To provide innovative, comprehensive solutions against all cyber threats targeting data and digital assets”, said Dr. Mohamed Reda, CEO of AEGIS.

Additionally, the company is pleased to announce that SOBAT Investment Company has committed to investing in this round, pending approval by the Committee on Foreign Investment in the United States (CFIUS). This relationship with SOBAT provides AEGIS with another avenue to accelerate initiatives further positioning AEGIS as a pioneer delivering the world’s leading data security solution, CyberGhost. SOBAT will also provide AEGIS with access to its deep connections and ties across Africa in order to advance cybersecurity in those areas.

“This initial investment is a testament to the support and belief in AEGIS’s potential to transform the battle against cyber threats into a safe cyber environment,” said Dr. Reda who continued, “and our next growth phase is looking at $50 million in fundraising.”

“We intend to build on this momentum with AEGIS by accelerating various planned initiatives to extend our geographic and market reach, by extending our technical leadership in advancing cybersecurity, and by initiating a series of strategic acquisitions,” said The Honorable Ronald R. Spoehel, Executive Chairman of AEGIS.

About AEGIS Cybersecurity Systems:

AEGIS Cybersecurity Systems, a pioneer in cutting-edge technology innovation, is revolutionizing the cybersecurity landscape by providing next-generation solutions designed to safeguard critical data and digital assets from the full spectrum of cyber threats. With a forward-thinking approach and relentless commitment to innovation, AEGIS leverages state-of-the-art advancements, including ghost technology, advanced encryption, proprietary blockchain, Generative AI-driven behavioral analysis, and Zero Trust Authentication, to deliver unparalleled data security and resilience.

By anticipating and countering emerging threats in real time, AEGIS empowers enterprises across industries and sectors to confidently navigate the complexities of an increasingly interconnected and digital-first world. AEGIS stands as a trusted partner, transforming the way cybersecurity challenges are addressed and ensuring its clients thrive in a secure, future-proof environment.

Media Contact:

Email: media@aegiscybersystems.com

Media Contact
Company Name: AEGIS Cybersecurity Systems
Contact Person: Media Manager
Email: Send Email
Country: United States
Website: https://www.aegiscybersystems.com/

Jeremy Parsons’ Single “The Garden” Hits #45 on Billboard Digital Songs Sales Chart

Country/Americana singer-songwriter Jeremy Parsons celebrates a career milestone as his deeply personal single, “The Garden,” hits #45 on the Billboard Digital Songs Sales Chart. Inspired by Parsons’ childhood memories and his reflections on mental well-being, the song has quickly resonated with audiences worldwide.

“The Garden” is an introspective and poignant track that draws on Parsons’ upbringing in Texas, where he spent much of his youth helping his father, Dr. Jerry Parsons, a renowned horticulturist, tend to the family garden. Initially a reluctant chore, gardening became a transformative experience that shaped Parsons’ perspective on life and mental health.

Reflecting on his inspiration for the song, Parsons shares, “I was raised in a garden, and I’m not talking about cabbage patch kid style. My Dad is Dr. Jerry Parsons, a horticulturist in Texas. I have many childhood memories of wishing I was somewhere playing with my friends instead of working in the dirt. As I got older, this shifted. I wanted to help, and I understood the connection. It was his great joy and passion, and he opened my eyes to see nothing like it.”

Years later, while living in East Nashville, Parsons witnessed a neighbor tending her own garden. The scene brought back memories of his father and sparked deeper thoughts about the psychological benefits of nurturing both plants and oneself. “It got my wheels turning and wondering what was going on in her life. How did that affect how she took care of the garden? How did that affect how she nurtured her own needs?”

“The Garden” invites listeners to view their mental health as a garden that requires attention, care, and nurturing. With heartfelt lyrics and a moving melody, the single underscores the importance of cultivating both inner and outer growth.

This achievement adds to Parsons’ growing list of accolades. A San Antonio native, he has built a reputation as one of Americana’s most authentic voices, blending Americana, Country, and Electronica into a sound uniquely his own. His previous releases, including “Humanity” and “Life Worth Dyin’ For,” have earned him critical acclaim, chart-topping success, and over 1.5 million Spotify streams. In 2024, Parsons was named Country Breakthrough Artist of the Year at the New Music Awards and a Finalist in the New Folk Competition.

Fans can stream “The Garden” on all major platforms and visit www.jeremyparsonsmusic.com for updates on upcoming projects and tour dates.

Media Contact
Company Name: MTS Management Group
Contact Person: Michael Stover
Email: Send Email
Phone: 4124455282
Address:227 Gill Road
City: Apollo
State: PA
Country: United States
Website: http://www.mtsmanagementgroup.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Jeremy Parsons’ Single “The Garden” Hits #45 on Billboard Digital Songs Sales Chart

Aqua Tower Reviews – A Detailed Report On This Advanced Water Generator System

Aqua Tower Reviews

Aqua Tower is an advanced home water generation system based on innovative water technology inspired by the military in certain countries worldwide. This off-grid, portable, and renewable water source is claimed to be ideal for addressing water scarcity issues in places where drought and humidity are challenging issues.

Richard Wilson, a third-generation farmer from California, claimed to have created it. This Aqua Tower review has been created to provide the reader with more insights into this water-independence device.

Visit The Aqua Tower Official Website For More Details

Rapidly gaining the title of the ‘petroleum of the 21st century’, water is an important resource that sustains life on this planet. However, water scarcity issues have become a daily reality in many parts of the world. It is in this context that sustainable water solutions such as Aqua Tower become relevant. But to ensure that this system is foolproof, one needs to go through every key aspect of this device.

The review here is crafted keeping that in mind and helps the reader to examine every single aspect of the system in detail. So keep on reading and grasp every bit of information on the Aqua Tower humidity-to-water converter system!

What Is Aqua Tower?

Based on the details from the official website, Aqua Tower can be identified as a DIY atmospheric water generator created by Richard Wilson, a third-generation farmer from California’s Imperial Valley. It is an easy-to-create, portable, off-grid water generator that can provide high-quality clean water throughout the year.

The system works using advanced technology and is inspired by the Military technique of extracting water from the air. This is a home water generation system that works by implementing a simple condensation principle. Aqua Tower is suitable for anyone who is looking for a sustainable, eco-friendly, and reliable water source that can provide purified water without toxins.

As per the creators, such a system can provide at least 60 gallons of water daily. The Aqua Tower water atmospheric water generator can be installed at home using the guide provided by the official website. It can be downloaded only using the official website and a 60-day money-back guarantee is provided with every purchase.

Working Of Aqua Tower System Explained

Aqua Tower works based on a simple condensation principle that is usually found to be used in air conditioners. According to this, the device converts the moisture in the air into clean and drinkable water. For this purpose, a built-in fan is installed along the device that helps to draw humid air from the environment.

Then using a cooling mechanism, this moisture-filled air is cooled below the dew point and then the water condenses into water droplets. In the next step, using a reservoir, these water droplets are collected. After this, this collected water undergoes a purification process which ensures that the water is free from any contaminants and toxins.

In the final stage, this water can be dispensed simply by a press of a button which provides one with fresh and purified water for one’s own needs.

About The Creator Of Aqua Tower Water Generator

As per the official website, Aqua Tower is created by Richard Wilson, a 46-year-old, third-generation farmer from Imperial Valley, on the outskirts of Salton City, California. Imperial Valley is known for its higher temperature and constant drought phenomena. Mr. Wilson had been living together with his family for a long time there even amid water scarcity.

But in 2015, things turned more gruesome and the water scarcity even started attacking him and his family on many levels. It was this incident that motivated Mr. Wilson to research and come up with an idea of a self-sufficient water system that is modeled after a technology used by the military in countries including the UK, the US, Israel, and India.

So with his friend Jason Mitchell, who was working in an air conditioning company at that time, Mr. Wilson came up with this pro-grade, off-grid power source which is a portable and self-sustained water resource.

Aqua Tower Review

What Is Inside The Aqua Tower Package?

One can find that Aqua Tower can be set using minimal installation and works based on advanced technology of thermodynamics and using the hygroscopic nature of water. Here are the key components of this air-to-water generator system.

Air filtration unit

One of the key components of this home water generation system is its air filtration unit. This unit helps to eliminate the pollutants and contaminants from the air before they reach the condensation coil. Such a system is highly beneficial, especially in areas where the air quality is compromised.

Condensation coils

The next key component of the Aqua Tower device is the condensation coils that are used for the water extraction process. In this system, there will be a compressor that circulates the filtered air and an evaporator that cools down the air into water droplets.

Water purification filters

The crucial stage in the Aqua Tower process is water purification and for this purpose, there is a multi-stage purification device available. So once the air reaches into dew point and melts down to water droplets, this then passes through the purification system to ensure no contaminants and impurities are included in it.

Storage Tank

Finally, the water that has been purified reaches into the storage tank where it is preserved for future uses. The water that is reached in the storage tank is pure and 100% free of impurities and can be reserved for years to come.

Tap Here To Check For A Free Download Of Aqua Tower On The Official Site

How To Use Aqua Tower System For Best Results?

As already mentioned Aqua Tower water from the air machine is simple to install and comes with a user-friendly design. The guide that is provided along the official website will detail a step-by-step system to assemble the components which anyone even without prior experience can do.

One doesn’t need any technical knowledge to install the system as the information provided in the guide is very simple to follow. One can find the materials needed for creating the system at nearby stores and also for a cheap price. The whole process only takes less than 1 hour to set up and install.

One is advised to set up the device in an area with less impurities and good air circulation. Also, it is recommended to connect the device to a power outlet that is generally used inside houses.

Key Features And Benefits Of The Aqua Tower

There are numerous benefits obtained from installing the Aqua Tower water condensation device and some of these include:

Provides purified and clean water anytime and anywhere
Continuous water supply without the need to depend on municipal systems and bottled water
Even works during emergencies and is portable and versatile
Environmentally friendly and energy efficient
Supports health by providing water that is free of toxins and contaminants
Lesser cost for installation and saves dollars from monthly water bills

Maximizing The Results Of Aqua Tower

According to the creator, this residential water generator can produce at least 60 gallons of water each day. However one can maximize the performance and effectiveness of the device by adding some simple steps.

Even though temperature and humidity can play a crucial role in how much water can be generated, one can make sure that the device is in good condition and give proper maintenance from time to time to enhance its efficiency. It is advised to clean the exterior of the device with a soft cotton cloth every month.

Also, the creators suggest changing the air filters every 3-6 months to ensure their purity. Another key recommendation is to change the water filters every once a year and proper sanitization of water tanks should be done every 3 months. Following these additional practices can ensure that the Aqua Tower water generator is in good condition and provides maximum output.

Check For A Free Download Of Aqua Tower On The Official Site – Click Here!

Aqua Tower Customer Reviews And Complaints

There have been multiple customer reviews online that detail the benefits of using the Aqua Tower atmospheric water harvester. People from different geographical areas and socio-economic backgrounds have claimed to have effective results from using the device.

According to most of them, following the blueprint for setting up this DIY atmospheric water generator is easy. These people claimed the device to be helpful, especially in areas where drought is a constant phenomenon. For them, it is one of the best atmospheric water generators available on the market today.

For other customers who live in off-grid cabins, this device became helpful as it is portable, sleek, and performs effortlessly. Most of the customers are satisfied with this eco-friendly water production system and claim to have been able to save dollars in water bills.

Only a few have complained of the device being ineffective and compared to the lion’s share of the positive reviews, these are very minimal.

Are There Any Risks Associated With Aqua Tower?

There are no risks or negative effects reported from the usage of the Aqua Tower water scarcity solutions system. This is primarily because such a device is created meticulously by experts and after years of research. The prototype has already been used by the army in some countries around the world.

Aqua Tower works using advanced technology and functions based on a simple condensation principle that is normally used in air conditioning devices. The multi-stage filtration system used in the device ensures no chemicals or impurities are in the water and kills the harmful microbes using an advanced UV light filtration system.

Not only the water is free of impurities, but also it is enriched with minerals and this shows that it is highly pure and safe for human consumption. Adding to that, the quality of the device is further ensured by authorized safety and quality standards inside the United States.

If given proper maintenance and required safety checks from time to time, there won’t be any risks in using the Aqua Tower device.

Pros And Cons Of The Aqua Tower

Having a clear-cut understanding of the different positive and negative aspects of this renewable water source is necessary before purchasing it. In this section, a detailed analysis of the pros and cons of this system is provided which will help the reader make a valid decision.

Pros

Innovative, eco-friendly, and energy-efficient
Cost-effective and portable water generator
Provides off-grid water supply
Simple and easy-to-understand instructions for installation
No prior experience is required for installation
Available with a step-by-step blueprint

Cons

Installation needs to be done without external help
The blueprint is available only from the Aqua Tower official website

On comparing this device with existing modes of water sources and supply, it can be understood that there are various positives to it and only a few negatives. The device offers a sustainable and off-grid water source that provides a steady supply of purified water throughout the year.

Also, it is cost-effective and available with a money-back guarantee. Because of these factors, it can be considered worth buying.

How Much Does Aqua Tower Guide Cost?

According to the official website, the Aqua Tower guide can be purchased for a cheaper price. This exclusive step-by-step system is available for only $39. 69. Earlier it was $149.00 per guide but now the price has been dropped.

Click Here To Get The Aqua Tower Blue Print From The Official Website

Where To Purchase Aqua Tower Blue Print?

Aqua Tower water generator guide can only be purchased from the official website and no other means of delivery is possible. The creators claim that its limited availability ensures the authenticity of the guide. One can’t find it elsewhere including any retail stores or e-commerce websites such as Amazon or eBay.

Or if anyone comes across similar guides, it might be replicas as there is currently an upsurge in replicas due to the popularity of Aqua Tower water condensation devices. So it is suggested to stick to the official website for downloading the guide. Also, the guide is not available for free download and one has to make a small amount of fee to access it.

But worry not, as the creators are ready to offer a 60-day money-back guarantee that ensures the financial stability of the customer. So if any one of the customers doesn’t feel satisfied with the product, this guarantee helps to claim a refund back within the next 60 days. The whole money will be refunded without any complications.

Final Verdict – Aqua Tower Reviews

A fair conclusion of the Aqua Tower reviews points out its authentic nature as a self-sufficient water system that works based on an innovative technology that functions on the simple condensation principle. This device is created by Richard Wilson, a third-generation farmer from California.

Aqua Tower provides a portable, off-grid, home water generation system that approximately provides around 60 gallons of water daily. It delivers an endless supply of purified water that will also help to cut down the bills spent on water. Aqua Tower is eco-friendly, energy-efficient, and also cost-effective.

There is no prior knowledge needed to set up this system and the instructions provided on the blueprint are easy to follow and provide a step-by-step guide. The main components of this system are an air filtration unit, a condensation coil for water extraction, multi-stage water purification filters, and a water storage tank.

Finally, the Aqua Tower system blueprint can be purchased for a small price from the official website where a 60-day money-back guarantee is also provided to ensure customer satisfaction.

FAQs About Aqua Tower

Is the Aqua Tower water generator costly to maintain?

There is no need to maintain it because it is a one-time build. So one won’t have to spend any extra money for maintenance.

Can individuals without prior expertise build it using this blueprint?

Absolutely. The blueprint for Aqua Tower includes all necessary information in a step-by-step process and one need not have any prior knowledge to build the device.

Why is Aqua Tower called environmentally friendly?

This atmospheric water harvester only uses recycled products and minimal things for installation. And once it starts working it needs only reduced power and energy to function as well.

How much time is needed to install this emergency water generator?

It only takes less than one hour to install the device.

How can one make the payment?

Customers can make the payment using either a credit card or PayPal.

Media Contact
Company Name: Webertise Solutions LLP
Contact Person: Stephen George
Email: Send Email
Phone: 9633533554
Address:114/3 2nd Floor, Kasi Arcade Thiyagaraya Nagar
City: Chennai
State: Tamil Nadu
Country: India
Website: webertise.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Aqua Tower Reviews – A Detailed Report On This Advanced Water Generator System

Bizitron Launches Initiative to Educate Businesses on Local Backlinks for SEO Success

Bizitron, a leader in digital marketing solutions, has launched a new initiative focused on educating businesses about the power of local backlinks for SEO success. This campaign will provide businesses with essential strategies, expert insights, and case studies to improve local visibility and drive organic traffic.

Bizitron, a leader in digital marketing solutions, is proud to announce the launch of its latest initiative aimed at educating businesses on the critical role of local backlinks in improving search engine rankings. This innovative campaign is designed to boost local visibility and drive organic traffic, empowering businesses to thrive in today’s competitive digital landscape.

With a focus on strategic backlink-building techniques, Bizitron new initiative will provide businesses with the tools and knowledge necessary to enhance their local SEO success. The campaign will feature a series of best practices, real-world case studies, and expert insights, all tailored to help businesses leverage local backlinks effectively.

“Local backlinks are a cornerstone of successful SEO strategies,” said Rayyan Syed, CEO of Bizitron. “By understanding and implementing these techniques, businesses can significantly enhance their online presence and gain a competitive edge in their industry.”

Through this initiative, Bizitron aims to demystify the complexities of local SEO and provide actionable strategies that businesses can implement immediately. The campaign will highlight the importance of building quality backlinks from local sources, which are essential for improving search engine rankings and driving meaningful engagement.

Bizitron commitment to excellence and results-driven approach ensures that businesses receive the highest level of support and guidance. By focusing on local SEO, the company continues to empower brands to connect with their audience and achieve sustainable growth.

For more information on Bizitron latest initiative and to learn how your business can benefit from enhanced local SEO strategies, visit their website or contact their team of experts.

Media Contact
Company Name: Bizitron
Contact Person: Rayyan Syed
Email: Send Email
Address:1309 Coffeen Avenue STE 1200
City: Sheridan
State: Wyoming 82801
Country: United States
Website: https://bizitron.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bizitron Launches Initiative to Educate Businesses on Local Backlinks for SEO Success

Multiple Sclerosis Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Multiple Sclerosis pipeline constitutes 75+ key companies continuously working towards developing 80+ Multiple Sclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Multiple Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Multiple Sclerosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple Sclerosis Market.

Some of the key takeaways from the Multiple Sclerosis Pipeline Report:

Companies across the globe are diligently working toward developing novel Multiple Sclerosis treatment therapies with a considerable amount of success over the years.
Multiple Sclerosis companies working in the treatment market are Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others, are developing therapies for the Multiple Sclerosis treatment

Emerging Multiple Sclerosis therapies in the different phases of clinical trials are- BIIB091, NeuroVax, IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others are expected to have a significant impact on the Multiple Sclerosis market in the coming years.
In January 2025, Pheno Therapeutics received clinical trial authorization (CTA) from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its small-molecule therapy, PTD802. This approval paves the way for the first-in-human trial of PTD802, a selective G protein-coupled receptor 17 (GPR17) antagonist, designed to promote remyelination in patients with neurological disorders, particularly multiple sclerosis (MS).
In January 2025, Contineum Therapeutics, Inc. (NASDAQ: CTNM), a clinical-stage biopharmaceutical company specializing in innovative therapies for neuroscience, inflammation, and immunology (NI&I) conditions, announced the successful completion of targeted enrollment for its Phase 2 PIPE-307 VISTA trial. A total of 168 patients have been enrolled in the study, which is evaluating PIPE-307, a potentially first-in-class M1 receptor antagonist, as a treatment for relapsing-remitting multiple sclerosis (RRMS).
In September 2024, Roche presented additional data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor, revealing nearly complete disease suppression in patients with relapsing multiple sclerosis (RMS) based on long-term findings. The company shared 48-week data for fenebrutinib from the FENopta open-label extension (OLE) study (NCT05119569), which followed a 12-week double-blind Phase II trial. This update comes shortly after Sanofi reported mixed results for its BTK inhibitor, tolebrutinib, where the HERCULES trial met its primary endpoint, but the two GEMINI trials did not.
In September 2024, Sanofi has revealed the results of its Phase III clinical trials for the investigational oral brain-penetrant BTK inhibitor, tolebrutinib, which is being developed for the treatment of multiple sclerosis (MS). The trials, known as HERCULES, GEMINI 1, and GEMINI 2, yielded mixed outcomes; while the HERCULES trial achieved its primary endpoint, the GEMINI trials did not. The HERCULES study specifically evaluated the efficacy and safety of tolebrutinib in patients with non-relapsing secondary progressive MS (nrSPMS) compared to a placebo.
In August 2024, TG Therapeutics, a partner of Precision Biosciences, has received approval from the US Food and Drug Administration (FDA) for an investigational new drug (IND) application to initiate a Phase I clinical trial of Azercabtagene Zapreleucel (azer-cel) for progressive forms of multiple sclerosis (MS). Azer-cel is an innovative allogeneic CAR T therapy developed by Precision BioSciences. Earlier this year, in January, Precision entered into a licensing agreement with TG Therapeutics, granting them global rights to azer-cel for autoimmune diseases, excluding cancer indications.
In August 2024, Indapta Therapeutics has received approval from the US Food and Drug Administration (FDA) for its investigational new drug (IND) application, paving the way for a future Phase I clinical trial of IDP-023 aimed at treating progressive multiple sclerosis (MS). IDP-023 is a g-natural killer (g-NK) cell therapy. The trial will be conducted by Stanford University and the University of California, San Francisco (UCSF) in the US.
In April 2024, Roche has released data from the Phase III OCARINA II study evaluating a subcutaneous (SC) injection of OCREVUS (ocrelizumab) in patients with relapsing or primary progressive multiple sclerosis (RMS or PPMS). OCREVUS is a humanized monoclonal antibody specifically designed to target CD20-positive B cells and is administered biannually through a ten-minute subcutaneous injection. This multicenter, global, randomized trial compared the pharmacokinetics, safety, and both radiological and clinical effects of OCREVUS delivered via SC injection to those of intravenous (IV) infusion.
In March 2024, NeuroGenesis Bio has announced favorable results from an interim analysis conducted during the open-label extension of a Phase II clinical trial for NG-01, aimed at treating progressive multiple sclerosis (MS). NG-01, the company’s leading candidate, is an autologous bone marrow-derived stem cell therapy designed to secrete higher levels of remyelinating and neurotrophic factors at the injury site within the central nervous system.

Multiple Sclerosis Overview

The most prevalent neurological condition affecting young adults is multiple sclerosis (MS), which often manifests as symptoms between the ages of 20 and 40. Myelin, also referred to as white matter, protects the central nervous system’s axons from damage in multiple sclerosis (MS).About 85% of MS patients have relapsing-remitting MS, which is the most prevalent type.

Get a Free Sample PDF Report to know more about Multiple Sclerosis Pipeline Therapeutic Assessment:

https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight

Emerging Multiple Sclerosis Drugs Under Different Phases of Clinical Development Include:

BIIB091: Biogen
NeuroVax: Immune Response BioPharma
IMCY-0141: ImCyse
ATA188: Atara Biotherapeutics
EHP-101: Emerald Health Pharmaceuticals
SAR441344: Sanofi
RC18: RemeGen
GB7208: Gossamer Bio
MRx0002: 4D Pharma
HuL001: HuniLife Biotechnology
ANK-700: Anokion
GSK3888130: GSK plc
Temelimab: GeNeuro
IMU-838: Immunic Therapeutics
Tolebrutinib: Sanofi
Fenebrutinib: Hoffman-La-Roche

Multiple Sclerosis Route of Administration

Multiple Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical.
Molecule Type

Multiple Sclerosis Molecule Type

Multiple Sclerosis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Multiple Sclerosis Pipeline Therapeutics Assessment

Multiple Sclerosis Assessment by Product Type
Multiple Sclerosis By Stage and Product Type
Multiple Sclerosis Assessment by Route of Administration
Multiple Sclerosis By Stage and Route of Administration
Multiple Sclerosis Assessment by Molecule Type
Multiple Sclerosis by Stage and Molecule Type

DelveInsight’s Multiple Sclerosis Report covers around 80+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Multiple Sclerosis product details are provided in the report. Download the Multiple Sclerosis pipeline report to learn more about the emerging Multiple Sclerosis therapies

Some of the key companies in the Multiple Sclerosis Therapeutics Market include:

Key companies developing therapies for Multiple Sclerosis are – Celgene, Actelion (now Janssen Pulmonary Hypertension), EMD Serono, Inc., Bayer, Acorda Therapeutics, Inc., Biogen, Teva Pharmaceuticals, Novartis, Sanofi, F. Hoffmann-La Roche Ltd, and others.

Multiple Sclerosis Pipeline Analysis:

The Multiple Sclerosis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Multiple Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple Sclerosis Treatment.
Multiple Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple Sclerosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Multiple Sclerosis drugs and therapies

Multiple Sclerosis Pipeline Market Drivers

Increasing Population with Multiple Sclerosis, extensive Approved therapies, wide range of R&D Pipeline, increasing Awareness are some of the important factors that are fueling the Multiple Sclerosis Market.

Multiple Sclerosis Pipeline Market Barriers

However, high cost of drugs, high Incidence of adverse events and other factors are creating obstacles in the Multiple Sclerosis Market growth.

Scope of Multiple Sclerosis Pipeline Drug Insight

Coverage: Global
Key Multiple Sclerosis Companies: Biogen, Immune Response BioPharma, ImCyse, Atara Biotherapeutics, Emerald Health Pharmaceuticals, Sanofi, RemeGen, Gossamer Bio, 4D Pharma, HuniLife Biotechnology, Anokion, GSK plc, GeNeuro, Immunic Therapeutics, Sanofi, Hoffman-La-Roche, and others
Key Multiple Sclerosis Therapies: BIIB091, NeuroVax, IMCY-0141, ATA188, EHP-101, SAR441344, RC18, GB7208, MRx0002, HuL001, ANK-700, GSK3888130, Temelimab, IMU-838, Tolebrutinib, Fenebrutinib, and others
Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies
Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers

Request for Sample PDF Report for Multiple Sclerosis Pipeline Assessment and clinical trials

Table of Contents

1. Multiple Sclerosis Report Introduction

2. Multiple Sclerosis Executive Summary

3. Multiple Sclerosis Overview

4. Multiple Sclerosis- Analytical Perspective In-depth Commercial Assessment

5. Multiple Sclerosis Pipeline Therapeutics

6. Multiple Sclerosis Late Stage Products (Phase II/III)

7. Multiple Sclerosis Mid Stage Products (Phase II)

8. Multiple Sclerosis Early Stage Products (Phase I)

9. Multiple Sclerosis Preclinical Stage Products

10. Multiple Sclerosis Therapeutics Assessment

11. Multiple Sclerosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Multiple Sclerosis Key Companies

14. Multiple Sclerosis Key Products

15. Multiple Sclerosis Unmet Needs

16 . Multiple Sclerosis Market Drivers and Barriers

17. Multiple Sclerosis Future Perspectives and Conclusion

18. Multiple Sclerosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Biogen, Immune Response BioPharma, Celgene, Novartis, Sanofi, Actelion

Idiopathic Pulmonary Fibrosis Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharma, Reviva Pharma, Roche

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Idiopathic Pulmonary Fibrosis pipeline constitutes 80+ key companies continuously working towards developing 100+ Idiopathic Pulmonary Fibrosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Idiopathic Pulmonary Fibrosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Idiopathic Pulmonary Fibrosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Idiopathic Pulmonary Fibrosis Market.

Some of the key takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report:

Companies across the globe are diligently working toward developing novel Idiopathic Pulmonary Fibrosis treatment therapies with a considerable amount of success over the years.
Idiopathic Pulmonary Fibrosis companies working in the treatment market are FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others, are developing therapies for the Idiopathic Pulmonary Fibrosis treatment

Emerging Idiopathic Pulmonary Fibrosis therapies in the different phases of clinical trials are- Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others are expected to have a significant impact on the Idiopathic Pulmonary Fibrosis market in the coming years.
In January 2025, Mediar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing first-in-class therapies to halt fibrosis progression, has announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a novel human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several severe diseases. A recently completed Phase 1 study in healthy volunteers demonstrated that MTX-463 was well-tolerated and successfully engaged WISP1 across all tested doses. The Phase 2 trial, scheduled to begin in the first half of 2025, will evaluate the safety, pharmacokinetics, and efficacy of MTX-463 in IPF patients, with Mediar conducting the trial. Upon completion of Phase 2, Lilly will assume responsibility for further clinical development and commercialization of the program.
In October 2024, Tvardi Therapeutics, Inc. (“Tvardi”), a clinical-stage biopharmaceutical company specializing in innovative oral small molecule therapies targeting STAT3 for the treatment of fibrosis-driven diseases, announced that its Chief Medical Officer, John Kauh, M.D., will present a poster at the CHEST 2024 Annual Meeting. This event, hosted by the American College of Chest Physicians, takes place from October 6–9 in Boston, Massachusetts. CHEST is recognized globally for its commitment to improving patient outcomes through cutting-edge chest medicine education, clinical research, and collaborative care initiatives.
In September 2024, Insilico Medicine has reported encouraging preliminary results from its Phase IIa clinical trial of ISM001-055, a small molecule drug developed using generative AI for the treatment of idiopathic pulmonary fibrosis (IPF). The randomized, double-blind, placebo-controlled trial was conducted at 21 sites in China, enrolling 71 patients with IPF. It evaluated the safety, tolerability, pharmacokinetics, and preliminary efficacy of 12 weeks of oral ISM001-055. The study included four groups: a placebo group, and three treatment groups receiving 30 mg once daily (QD), 30 mg twice daily (BID), and 60 mg QD.
In July 2024, South Korean biotechnology company Bridge Biotherapeutics has completed enrollment for its Phase II clinical trial of BBT-877, a novel autotaxin inhibitor developed for the treatment of idiopathic pulmonary fibrosis (IPF).
In May 2024, Aileron Therapeutics has announced positive results from the first cohort of its ongoing Phase Ib clinical trial evaluating inhaled LTI-03 in patients with idiopathic pulmonary fibrosis (IPF). This randomized, double-blind, placebo-controlled, multicenter dose-escalation study includes recently diagnosed IPF patients who have not received anti-fibrotic treatment for at least two months

Idiopathic Pulmonary Fibrosis Overview

Idiopathic Pulmonary Fibrosis (IPF) is a chronic and progressive lung disease characterized by the scarring (fibrosis) of the lung tissue. In IPF, the lung tissue becomes thickened, stiff, and scarred over time, making it difficult for the lungs to function properly and limiting the ability to breathe.

Get a Free Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/idiopathic-pulmonary-fibrosis-pipeline-insight

Emerging Idiopathic Pulmonary Fibrosis Drugs Under Different Phases of Clinical Development Include:

Pamrevlumab: FibroGen
Tipelukast: MediciNova
PLN-74809: Pliant Therapeutics
HZN-825: Horizon Pharmaceuticals
Brilaroxazine: Reviva Pharmaceuticals
PRM-151: Roche
C21: Vicore Pharma
TXR 1002: Aria Pharmaceuticals
INS018_055: InSilico Medicine
AD-214: AdAlta
AZD5055: AstraZeneca
LTI-03: Lung Therapeutics
CSL312: CSL Behring
GB0139: Galecto Biotech AB
PLN-74809: Pliant Therapeutics
ENV-101: Endeavor BioMedicine
Pamrevlumab: FibroGen
BI-1015550: Boehringer Ingelheim

Idiopathic Pulmonary Fibrosis Route of Administration

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Idiopathic Pulmonary Fibrosis Molecule Type

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

Idiopathic Pulmonary Fibrosis Assessment by Product Type
Idiopathic Pulmonary Fibrosis By Stage and Product Type
Idiopathic Pulmonary Fibrosis Assessment by Route of Administration
Idiopathic Pulmonary Fibrosis By Stage and Route of Administration
Idiopathic Pulmonary Fibrosis Assessment by Molecule Type
Idiopathic Pulmonary Fibrosis by Stage and Molecule Type

DelveInsight’s Idiopathic Pulmonary Fibrosis Report covers around 100+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Idiopathic Pulmonary Fibrosis product details are provided in the report. Download the Idiopathic Pulmonary Fibrosis pipeline report to learn more about the emerging Idiopathic Pulmonary Fibrosis therapies

Some of the key companies in the Idiopathic Pulmonary Fibrosis Therapeutics Market include:

Key companies developing therapies for Idiopathic Pulmonary Fibrosis are – Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche Ltd, FibroGen Inc., MediciNova Inc., Jubliant Pharma Limited (Jubliant Cadista Limited), Merck & Co. Inc., United Therapeutics, Boehringer Ingelheim International GmbH, Horizon Therapeutics Inc., Avalyn Pharma Inc., CS Pharmaceuticals, and others.

Idiopathic Pulmonary Fibrosis Pipeline Analysis:

The Idiopathic Pulmonary Fibrosis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Idiopathic Pulmonary Fibrosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Idiopathic Pulmonary Fibrosis Treatment.
Idiopathic Pulmonary Fibrosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Idiopathic Pulmonary Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Idiopathic Pulmonary Fibrosis market.

Download Sample PDF Report to know more about Idiopathic Pulmonary Fibrosis drugs and therapies

Idiopathic Pulmonary Fibrosis Pipeline Market Drivers

Changing lifestyle patterns and increasing consumption of nicotine products, diverse and extensive pipeline therapies, rise in the number of geriatric population are some of the important factors that are fueling the Idiopathic Pulmonary Fibrosis Market.

Idiopathic Pulmonary Fibrosis Pipeline Market Barriers

However, Lack of effective treatment options for severe Idiopathic Pulmonary Fibrosis (IPF) cases, exact Cause of IPF is not fully understood, misdiagnosis of Idiopathic Pulmonary Fibrosis (IPF) and other factors are creating obstacles in the Idiopathic Pulmonary Fibrosis Market growth.

Scope of Idiopathic Pulmonary Fibrosis Pipeline Drug Insight

Coverage: Global
Key Idiopathic Pulmonary Fibrosis Companies: FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharmaceuticals, Reviva Pharmaceuticals, Roche, Vicore Pharma, Aria Pharmaceuticals, InSilico Medicine, AdAlta, AstraZeneca, Lung Therapeutics, CSL Behring, Galecto Biotech AB, Pliant Therapeutics, Endeavor BioMedicine, FibroGen, Boehringer Ingelheim, and others
Key Idiopathic Pulmonary Fibrosis Therapies: Pamrevlumab, Tipelukast, PLN-74809, HZN-825, Brilaroxazine, PRM-151, C21, TXR 1002, INS018_055, AD-214, AZD5055, LTI-03, CSL312, GB0139, PLN-74809, ENV-101, Pamrevlumab, BI-1015550, and others
Idiopathic Pulmonary Fibrosis Therapeutic Assessment: Idiopathic Pulmonary Fibrosis current marketed and Idiopathic Pulmonary Fibrosis emerging therapies
Idiopathic Pulmonary Fibrosis Market Dynamics: Idiopathic Pulmonary Fibrosis market drivers and Idiopathic Pulmonary Fibrosis market barriers

Request for Sample PDF Report for Idiopathic Pulmonary Fibrosis Pipeline Assessment and clinical trials

Table of Contents

1. Idiopathic Pulmonary Fibrosis Report Introduction

2. Idiopathic Pulmonary Fibrosis Executive Summary

3. Idiopathic Pulmonary Fibrosis Overview

4. Idiopathic Pulmonary Fibrosis- Analytical Perspective In-depth Commercial Assessment

5. Idiopathic Pulmonary Fibrosis Pipeline Therapeutics

6. Idiopathic Pulmonary Fibrosis Late Stage Products (Phase II/III)

7. Idiopathic Pulmonary Fibrosis Mid Stage Products (Phase II)

8. Idiopathic Pulmonary Fibrosis Early Stage Products (Phase I)

9. Idiopathic Pulmonary Fibrosis Preclinical Stage Products

10. Idiopathic Pulmonary Fibrosis Therapeutics Assessment

11. Idiopathic Pulmonary Fibrosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Idiopathic Pulmonary Fibrosis Key Companies

14. Idiopathic Pulmonary Fibrosis Key Products

15. Idiopathic Pulmonary Fibrosis Unmet Needs

16 . Idiopathic Pulmonary Fibrosis Market Drivers and Barriers

17. Idiopathic Pulmonary Fibrosis Future Perspectives and Conclusion

18. Idiopathic Pulmonary Fibrosis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | FibroGen, MediciNova, Pliant Therapeutics, Horizon Pharma, Reviva Pharma, Roche

Protheragen Introduces One-Stop Therapeutic Development Solutions to Accelerate Ophthalmic Drug Research

Protheragen launches a full spectrum of ophthalmic drug preclinical R&D services to streamline the complex process of developing effective therapies for eye diseases.

Protheragen, a reputable research service provider in the life science industry, proudly introduces its comprehensive therapeutic development solutions covering a full spectrum of ophthalmic drug preclinical R&D services tailored specifically for ophthalmic research. These innovative initiatives help researchers streamline the complex process of developing effective therapies for eye diseases, ultimately transforming the landscape of ocular health.

With the rising prevalence of ophthalmic conditions such as glaucoma, dry eye, diabetic retinopathy, and age-related macular degeneration (AMD), the need for efficient ophthalmic drug development has never been more urgent. Excitingly, the past decade has witnessed a remarkable surge of advancements in the field of ophthalmic drug discovery as evidenced by the steady stream of FDA approvals for groundbreaking therapeutics. Many innovative therapeutic strategies, including gene therapy, stem cell therapy, and targeted modulation of pathways have opened up new avenues for tissue repair, regeneration, and achieving lasting therapeutic benefits.

As a preclinical research service company actively engaged in ophthalmic disease research, Protheragen provides researchers and pharmaceutical companies with comprehensive preclinical R&D services, from target identification and validation to in vivo and in vitro model customization services for ophthalmic disorders. For different eye diseases, Protheragen will customize development plans that prioritize individual research goals, ensuring a targeted approach to addressing specific ophthalmic conditions. Using state-of-the-art research facilities and techniques such as high-throughput screening platforms and advanced analytical instrumentation, Protheragen is confident it can accelerate the discovery and development of innovative ocular therapies.

Apart from preclinical ophthalmic R&D services, Protheragen is also an ophthalmic biological samples supplier providing ready-to-ship products for researchers. These featured products encompass ocular cells, aqueous humor, tear samples, and tissue samples, all of which are carefully processed to maintain integrity and viability for research use. In conclusion, Protheragen is dedicated to supporting ophthalmic research and works closely with customers to provide tailored solutions that improve the effectiveness and precision of their investigations.

About Protheragen

Protheragen is a research service provider offering extensive solutions for the development of therapies targeting rare ophthalmic diseases, including congenital eye diseases, hereditary eye diseases, infectious eye diseases, autoimmune eye diseases, and ocular tumor diseases. Its service portfolio encompasses diagnostic development, diverse therapy development, disease model creation, and preclinical research services, all tailored to meet the unique requirements of global clients.

Media Contact
Company Name: Protheragen
Contact Person: Selina Green
Email: Send Email
Country: United States
Website: https://www.protheragen.us/ophthalmic-disease/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Protheragen Introduces One-Stop Therapeutic Development Solutions to Accelerate Ophthalmic Drug Research

The AI Lead by Dr. Brian Lambert Offers a Powerful Roadmap on How to Overcome Data Drag and Accelerate Digital Dominance in the Age of AI

Brian Lambert’s The AI Lead is a comprehensive AI treatise for middle managers to tackle data drag, achieve digital mastery, and advance their organization’s data maturity. Blending strategy with cutting-edge technology, the book empowers leaders to make data actionable and lead with clarity in the AI age.

Brian Lambert, Ph.D., is a seasoned expert in digital transformation and leadership development, with over 20 years of experience guiding organizations toward technological excellence. As a thought leader in blending strategy with technology, Brian has worked with global firms and Fortune 500 companies to optimize data-driven decision-making and accelerate change.

He is the author of The AI Lead: Overcoming Data Drag to Accelerate Digital Dominance, a pivotal book designed to empower middle managers to lead with clarity and impact in the AI age. Known for his pragmatic insights and actionable frameworks, he champions the “Digital First, Job Second” philosophy—emphasizing digital fluency as the key to staying competitive in the modern business landscape. Featured in Forbes and MarketWatch, he is a sought-after coach and keynote speaker, known for equipping organizations with the tools they need to achieve digital mastery in an AI-powered world.

This one-on-one interview shares Brian’s background and experience writing The AI Lead: Overcoming Data Drag to Accelerate Digital Dominance.

Tell us about The AI Lead: Overcoming Data Drag to Accelerate Digital Dominance.

The AI Lead is a practical roadmap for leaders tasked with navigating the complexities of digital transformation. With over 20 years of experience in organizational management and technology, I’ve seen firsthand how “data drag”—the inefficiencies caused by siloed data and outdated systems—can stifle innovation, slow progress, and leave organizations struggling to compete. This book is my guide to helping readers overcome these challenges, harness the full potential of artificial intelligence, and transform their organization into digital leaders.

AI is far more than chatbots or simple tools; it’s a strategic force that, when integrated across an organization, drives operational efficiency, agility, and innovation. I’ll show you how to align AI and big data with your organizational goals, breaking through technical and cultural barriers to future-proof your business in a rapidly evolving digital landscape.

Inside, you’ll find proven strategies to eliminate data inefficiencies, practical frameworks to integrate AI seamlessly, and real-world case studies that demonstrate what’s possible. I also emphasize the importance of ethical AI practices and people-centered leadership—because true digital transformation requires both cutting-edge technology and human ingenuity.

Ultimately, my goal is to show you how to align data-driven insights with organizational goals, creating agility and resilience in the face of constant change.

What inspired you to write The AI Lead: Overcoming Data Drag to Accelerate Digital Dominance?

According to McKinsey, 70% of digital transformations fail. This is a result of many factors, but most often stems from a lack of understanding, outdated systems, unclear strategies, fear of obsolescence, or discomfort with new workflows. Yet, according to SAP, organizations who prioritize digital transformation report up to 45% revenue growth following their transformation efforts, so the benefits of leveraging digital technologies are clear.

Through The AI Lead, my goal is to empower middle managers to become the driving force behind meaningful AI-powered digital change. The book bridges the gap between abstract strategy and practical implementation, offering clear steps to unlock the full potential of AI and data for organizational success.

How did your background and experience influence your writing?

My career has been rooted in guiding teams and organizations through digital transformation and data-driven decision-making. Over two decades, I’ve worked in technology and business in many different industries, blending strategic foresight with the hands-on implementation of emerging technologies. This firsthand experience has taught me the critical importance of the partnership of technology and leadership in accelerating change, which inspired me to create an actionable blueprint tailored specifically for their unique challenges.

What is one message you would like readers to remember?

Leaders hold the key to digital transformation, and with the right strategies, they can break through barriers to create lasting impact. I want readers to embrace the intersection of technology and strategy and walk away with the confidence they need to harness data and AI to drive innovation and lead their teams toward a future of sustained success.

Purchasing the Book

The AI Lead: Overcoming Data Drag to Accelerate Digital Dominance has received positive reviews from well-known literary organizations, authors, and reviewers around the world. Bruce Galinsky, Senior Test Program Manager at NTT Data writes, “Unlike typical tech guides, [The AI Lead] simplifies AI adoption through clear analogies, actional steps, and real world examples, providing an inspiring, adaptable framework for integrating AI smoothly into operations.”

With its worldwide release on January 14th, 2025, the book is currently available for sale on Amazon, Barnes & Noble, Nook, and other online bookstores and can be purchased here: https://www.amazon.com/AI-Lead-Overcoming-Accelerate-Dominance/dp/B0DLY8FWX2/

To connect with Brian and learn more about his work, visit: https://AiLeadBook.com and https://www.DrBrianLambert.com. You can also find him on LinkedIn, YouTube, and X.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The AI Lead by Dr. Brian Lambert Offers a Powerful Roadmap on How to Overcome Data Drag and Accelerate Digital Dominance in the Age of AI

Irritable Bowel Syndrome Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Bio

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Irritable Bowel Syndrome pipeline constitutes 24+ key companies continuously working towards developing 24+ Irritable Bowel Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Irritable Bowel Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Irritable Bowel Syndrome Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Irritable Bowel Syndrome Market.

Some of the key takeaways from the Irritable Bowel Syndrome Pipeline Report:

Companies across the globe are diligently working toward developing novel Irritable Bowel Syndrome treatment therapies with a considerable amount of success over the years.
Irritable Bowel Syndrome companies working in the treatment market are P4 Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others, are developing therapies for the Irritable Bowel Syndrome treatment

Emerging Irritable Bowel Syndrome therapies such as – P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others are expected to have a significant impact on the Irritable Bowel Syndrome market in the coming years.
In October 2024, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a healthcare company specializing in gastrointestinal conditions, is set to present new subgroup analysis findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course. The analyses, derived from the primary endpoint of the pivotal Phase III STARS trial, assess the treatment effect of apraglutide based on baseline demographics and disease-specific characteristics in adults with short bowel syndrome with intestinal failure (SBS-IF). The oral presentation, reveals that apraglutide demonstrated a consistent treatment effect across various subgroups, including gender, age, body weight, region, race, ethnicity, and SBS characteristics, such as remnant bowel length. These results complement the previously reported positive outcomes from the pivotal Phase III trial.
In February 2024, CinPhloro Pharma, part of the CinRx portfolio, is developing CIN-103 as an innovative treatment for irritable bowel syndrome with predominant diarrhea (IBS-D). The company announced that the first participant in its Phase 2 enviva study has been dosed. CIN-103, a novel phloroglucinol formulation designed for long-term use, is a non-opioid small molecule targeting multiple IBS-D mechanisms, including motility, secretion, pain, spasms, and inflammation.

Irritable Bowel Syndrome Overview

Irritable Bowel Syndrome is a chronic, often debilitating, functional gastrointestinal (GI) disorder. It can begin in childhood, adolescence, or adulthood and can resolve unexpectedly for periods throughout an individual’s lifespan, recurring at any age. The condition causes recurrent attacks of abdominal pain or discomfort in association with bowel habits. The most important single risk factors are female gender, younger age and preceding gastrointestinal infections.

Get a Free Sample PDF Report to know more about Irritable Bowel Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/irritable-bowel-syndrome-ibs-pipeline-insight

Emerging Irritable Bowel Syndrome Drugs Under Different Phases of Clinical Development Include:

P4M01: P4Microbiome
BMC426: Biomica
ORP-101: OrphoMed
INVA 8002: Invea Therapeutics, Inc.
RQ-00310941: RaQualia Pharma
RHB-102: RedHill Biopharma Ltd.
Blautix: 4D pharma
Rifamycin: SV-MMX Cosmo Pharmaceuticals

Route of Administration

Irritable Bowel Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Molecule Type

Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Irritable Bowel Syndrome Pipeline Therapeutics Assessment

Irritable Bowel Syndrome Assessment by Product Type
Irritable Bowel Syndrome By Stage and Product Type
Irritable Bowel Syndrome Assessment by Route of Administration
Irritable Bowel Syndrome By Stage and Route of Administration
Irritable Bowel Syndrome Assessment by Molecule Type
Irritable Bowel Syndrome by Stage and Molecule Type

DelveInsight’s Irritable Bowel Syndrome Report covers around 24+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Irritable Bowel Syndrome product details are provided in the report. Download the Irritable Bowel Syndrome pipeline report to learn more about the emerging Irritable Bowel Syndrome therapies

Some of the key companies in the Irritable Bowel Syndrome Therapeutics Market include:

Key companies developing therapies for Irritable Bowel Syndrome are – Allergan, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals Inc., Bausch Health, Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synthetic Biologics, Inc., Astellas Pharma, Inc., and Ardelyx, and others.

Irritable Bowel Syndrome Pipeline Analysis:

The Irritable Bowel Syndrome pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Irritable Bowel Syndrome with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Irritable Bowel Syndrome Treatment.
Irritable Bowel Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Irritable Bowel Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Irritable Bowel Syndrome market.

Download Sample PDF Report to know more about Irritable Bowel Syndrome drugs and therapies

Irritable Bowel Syndrome Pipeline Market Drivers

Increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit, surge in the level of Unhealthy lifestyle are some of the important factors that are fueling the Irritable Bowel Syndrome Market.

Irritable Bowel Syndrome Pipeline Market Barriers

However, complex diagnostic processes, lack of awareness and other factors are creating obstacles in the Irritable Bowel Syndrome Market growth.

Scope of Irritable Bowel Syndrome Pipeline Drug Insight

Coverage: Global
Key Irritable Bowel Syndrome Companies: P4Microbiome, Biomica, Invea Therapeutics, Inc., RaQualia Pharma, RedHill Biopharma Ltd., 4D pharma, SV-MMX Cosmo Pharmaceuticals, and others
Key Irritable Bowel Syndrome Therapies: P4M01, BMC426, INVA 8002, RQ-00310941, RHB-102, Blautix, Rifamycin, and others
Irritable Bowel Syndrome Therapeutic Assessment: Irritable Bowel Syndrome current marketed and Irritable Bowel Syndrome emerging therapies
Irritable Bowel Syndrome Market Dynamics: Irritable Bowel Syndrome market drivers and Irritable Bowel Syndrome market barriers

Request for Sample PDF Report for Irritable Bowel Syndrome Pipeline Assessment and clinical trials

Table of Contents

1	Irritable Bowel Syndrome Report Introduction
2	Irritable Bowel Syndrome Executive Summary
3	Irritable Bowel Syndrome Overview
4	Irritable Bowel Syndrome- Analytical Perspective In-depth Commercial Assessment
5	Irritable Bowel Syndrome Pipeline Therapeutics
6	Irritable Bowel Syndrome Late Stage Products (Phase II/III)
7	Irritable Bowel Syndrome Mid Stage Products (Phase II)
8	Irritable Bowel Syndrome Early Stage Products (Phase I)
9	Irritable Bowel Syndrome Preclinical Stage Products
10	Irritable Bowel Syndrome Therapeutics Assessment
11	Irritable Bowel Syndrome Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Irritable Bowel Syndrome Key Companies
14	Irritable Bowel Syndrome Key Products
15	Irritable Bowel Syndrome Unmet Needs
16	Irritable Bowel Syndrome Market Drivers and Barriers
17	Irritable Bowel Syndrome Future Perspectives and Conclusion
18	Irritable Bowel Syndrome Analyst Views
19	Appendix
20	About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Irritable Bowel Syndrome Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | P4 Microbiome, Biomica, Invea Therapeutics, RaQualia Pharma, RedHill Bio